Login / Signup

Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).

Marcus Werner Koch
Published in: Journal of neurology, neurosurgery, and psychiatry (2023)
Keyphrases
  • multiple sclerosis
  • phase iii
  • study protocol
  • white matter
  • phase ii
  • clinical trial
  • open label
  • randomized controlled trial
  • mass spectrometry
  • ms ms
  • systemic lupus erythematosus
  • double blind